LENZ Therapeutics (LENZ) logo

LENZ Therapeutics (LENZ) stock

Eye drop medicines , market cap $105M

After-hours Fri
$3.00
+1.18%

Close $2.97 -11.23%

Why is LENZ down?

Down 89% in a year while the S&P 500 rose 7%.

  • Its loss grew from $49.8M in fiscal 2024 to $82.1M in fiscal 2025.

Sources: Price history, Nov 20, 2026; Annual reports, Dec 31, 2025

−3Long-term trend below a falling 200-day average, down over one year, down over two years

Tell me next time LENZ moves

Free account, no card. An optional alert when LENZ moves or its score changes.Pro, $1 for a first month. An optional alert when LENZ moves or its score changes.Pro, 7 days free with a card. An optional alert when LENZ moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on LENZ →2 more reasons why LENZ lags the market, from its filings, with the other side and the timeline, for Pro members.
Quality Score
-11
Poor
In its industry
#269of 273
Checks firing
1of 14
Transition
From 52-week high
-90.8%
under its best in a year

LENZ's Quality Score fell 2 points on Fri, Nov 20, to -11. It closed away from its high of the day (2 chart checks stopped).

Follow LENZ's news. Pro members can get an alert when LENZ Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when LENZ files newsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Cash$197M, about 6 quarters at the last year's spendingOn Sep 30

Key facts on LENZ

Key facts on LENZ
Holding it backMoves 12.2% a day with no profit behind it
Its scoreDown:Lowest Quality Score since May 2024 Scores before Sep 10, 2026 were rebuilt.
Latest filing10-Q, Nov 3 Filed its quarterly report (10-Q) for the quarter to Sep 30, 2026

LENZ in the news

Big story

Wed Oct 28: Leadership

LENZ Therapeutics filed an 8-K reporting a change of CEO

LENZ closed −12.6% that day on 2.8x normal volume.

From the company's SEC filing

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$197M, about 6 quarters at the last year's spendingOn Sep 30

LENZ catalysts

Coming up

After its last 4 reports it closed -8.3% on average, higher 1 of 4 times.

3 past catalysts since 2025, with sizes and sources, for Pro members.

What's next for LENZ, and how long its cash lasts

Cash runway Sep 30 balance sheet

About 6 quarters

$197M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Apr 4, 2025)
  • At-the-market share sales program (424B5, filed Apr 14, 2025)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

Director Jeffrey P. George bought 5,592 shares on Mar 27. 2 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Evert Schimmelpennink’s 11 filings and quotes.

Get an alert when LENZ files newsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How LENZ ranks in Biotech

LENZ is #269 of 273 by Quality Score.

How LENZ ranks in Biotech
RankStockQuality Score
269LENZ Therapeutics (LENZ) logoLENZLENZ Therapeutics-11

More in Biotech

When does LENZ report earnings, and what happens after?

Expected to report Tue Mar 23, after the close (in 122 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What LENZ reported on Oct 28, 2026

The quarter

Sales of $3.4M, 73% less than a year ago; a loss of $0.99 a share, from $0.59.

“These increases were primarily driven by our launch investment, with increases in commercial marketing, advertising, sales infrastructure, and personnel-related expenses due to a growth in headcount.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

Where the quarter's sales came from
LineQ3
2026
Q2
2026
Q3
2025
By product
Product$2.6M77%$1.7M32%––

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 3)

1 more line, for Pro members.

The outlook

The outlook the company gave, by period
MeasureFigure
Full year 2027
Operating expenses$70M to $75M

Figures as filed (SEC filing, Oct 28)

The numbers

Market value
$105M
today
Sales
$12.4M
down 29.4% on the year
Free cash flow
-$128M
last 12 months

2 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on LENZ: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-20.8%-3.3%+8.7%
May 11Aug 11Oct 28
ReportedGapReaction5
days
Oct 28, 2026After close-6.5%+8.7%+7.8%
Aug 11, 2026After close+13.8%-3.3%-8.4%
May 11, 2026After close-23.1%-20.8%-30.9%

LENZ closed higher after 1 of its last 4 reports.

All 4 reports, and LENZ's Quality Score going into each

LENZ sales and profit by year

Profit by year

Sales grew in 2025, to $19.1M. It lost money in both years.

LENZ has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on LENZ, and all 14 on every stock.Get in free →See the top 3 →Start Pro

LENZ RSI on Nov 20: 39.2, below its 50-day and 200-day averages

Not scored

RSI 39.2, MACD below signal, below both averages. Not scored.

The deep dive on LENZ

10 more findings on LENZ, each with its source, for Pro members.

LENZ share count over time

10% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of LENZ outstanding, as filed
Shares
outstanding
As
of
31.4MOct 28, 2026
31.4MAug 5, 2026
31.4MMay 5, 2026
31.4MMar 18, 2026
Offerings, shelves, and splits of LENZ, from its filings
From its
filings
Filed
Set up an at-the-market program for up to $150M of shares, about 143% of its market valueApr 14, 2025
Registered shares for a later sale (S-3)Apr 4, 2025
Registered shares for sale (S-1)Sep 11, 2024
Registered shares for sale (S-1)Mar 29, 2024

LENZ insider trades

One insider sold $9.1M across 3 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellRA Capital Management, L.P.$7.3M10% ownerat $3.36 on Oct 29, filed Nov 2

All 3 insider filings on LENZ from the last six months, for Pro members.

All LENZ insider trades

LENZ's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

Which ETFs hold LENZ?

In ETFs: LENZ is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About LENZ Therapeutics

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.

152 employeesSolana Beach, CAlenz-tx.com

What LENZ Therapeutics says it competes with

“The biotechnology, pharmaceutical, and ophthalmology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on intellectual property.”

From its annual report, SEC filing · Mar 24, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on LENZ and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn LENZ's score around: 9 things
  • 7 more filings explained, a plain line each
  • 7 more things pulling LENZ's score down
BreakawayNov 2RA Capital Management, L.P. sold LENZ$7.3M at $3.36, filed Nov 2

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: LENZ's Quality Score is -11 (Poor), #269 of 273 in Biotech. Insiders sold $9.1M in the last 6 months (Form 4).

What does LENZ's Quality Score say?

LENZ scores -11 today, which Breakaway calls Poor. It is #269 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 89% in a year while the S&P 500 rose 7%. Cash lasts about 6 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is LENZ's Quality Score?

LENZ scores -11 today, which Breakaway calls Poor (below zero). That is #269 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind LENZ's -11.

Are insiders buying LENZ?

One insider sold $9.1M across 3 filings in the last 6 months. No open-⁠market buys on record. The newest is RA Capital Management, L.P., 10% owner, who sold $7.3M on Oct 29. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for LENZ Therapeutics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.